Table 6.

Subgroup analysis of included randomized controlled trials for the effect of CoQ10 supplementation on HOMA-IR.

Group	No. of trials (participates)	WMD (95% CI)	Pdifferencea	I2, %	Pheterogeneityb	Pc for between subgroup heterogeneity
Overall	18 (988)	−0.69(−1.00, −0.38)	<0.001	88.80	<0.001
Study design
Parallel	18 (988)	−0.69(−1.00, −0.38)	<0.001	88.80	<0.001
Duration (week)
<12	8 (374)	−0.24(−0.52, 0.05)	0.11	79.45	0.00	<0.001
≥12	10 (614)	−1.03(−1.40, −0.65)	<0.001	61.13	0.01
CoQ10 dosage
<200 mg/day	10 (597)	−0.97(−1.44, −0.50)	<0.001	80.99	<0.001	0.10
≥200 mg/day and <300 mg/day	7 (356)	−0.54(−1.17, 0.10)	0.10	93.79	<0.001
≥300 mg/day	1 (35)	−0.20(−0.72, 0.32)	0.45	-	-
Control group
Placebo	16 (907)	−0.76 (−1.13, −0.39)	<0.001	89.72	<0.001	0.53
Other	2 (81)	−0.47 (−1.31, 0.36)	0.27	82.16	0.02
Quality of study
High	1 (40)	−1.38 (−3.60, 0.84)	0.22	-	-	0.54
Low	17 (948)	−0.68 (−1.00, −0.37)	<0.001	89.38	<0.001
Received industry funding?
Yes	5 (234)	0.03(−0.33, 0.40)	0.86	63.99	0.03	<0.001
No	13 (754)	−0.99(−1.42, −0.55)	<0.001	90.72	<0.001

Abbreviations: WMD, weighted mean difference; CI, confidence interval; CoQ10, coenzyme Q10.

^aDersimonian–Laird random effect model was used to calculate the effect size and P-value.

^bCochrane Q test was used to detect the heterogeneity between studies.

^cCochrane Q test was used to detect the subgroup heterogeneity.